Table 2.
Estimated Antibody Waning and Seroreversion Rates
| HCoV Type | Rate (95% CI), y−1 | |||
|---|---|---|---|---|
| Anti-S IgG Antibody Waning Ratea | Anti-S IgG Seroreversion Ratea | |||
| Children (Aged <10 y) | Adults (Aged >10 y) | Children (Aged <10 y) | Adults (Aged >10 y) | |
| NL63 | 0.47 (.41–.54) | 0.25 (.24–.27) | 1.37 (.15–11.73) | 0.72 (.08–6.32) |
| 229E | 0.38 (.31–.46) | 0.27 (.26–.28) | 0.31 (.05–2.01) | 0.22 (.03–1.41) |
| OC43 | 0.22 (.17–.28) | 0.13 (.12–.15) | 0.32 (.05–1.98) | 0.19 (.03–1.17) |
| HKU1 | 0.39 (.33–.45) | 0.17 (.16–.19) | 0.63 (.09–4.55) | 0.29 (.04–2.10) |
Abbreviations: CI, confidence interval; HCoV, human coronavirus; Ig, immunoglobulin; S, spike.
a
Antibody waning rates are estimated from linear mixed-effects regression models applied to data from the COVID-Oise longitudinal data. Seroreversion rates are calculated based on antibody waning rates from the COVID-Oise study and seropositivity cutoffs from the SeroPed study.